The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
The 2022 Tandem Meetings | Outcomes of alloHSCT in TP53-mutated AML and MDS
Muhammad Umair Mushtaq, MD, University of Kansas Medical Center, Westwood, KS, discusses the role of allogeneic hematopoietic stem cell transplantation (alloHSCT) in patients with TP53-mutated acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). According to Dr Mushtaq, although the outcomes of patients with AML and MDS remain very poor after alloHSCT, it still provides a survival benefit in this difficult-to-treat patient population. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
